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With the advent of in vitro immunologic testing, we can now detect exposed individuals who are
sensitized to beryllium and those who have chronic beryllium disease (CBD) with lung pathology
and impairment. Earlier detection and more accurate diagnostic tools raise new questions about
the natural history of sensitization and granulomatous disease. Preliminary data suggest that early
detection identifies people who are sensitized to beryllium and that these individuals are at risk
for progressing into clinical disease. This article discusses the historical, recent, and ongoing
studies germane to our understanding of CBD natural history, including the immunologic and
inflammatory basis of the disease, the environmental and host risk factors for disease progression,
biological markers of disease severity and activity that may help predict outcome, and the
implications for broad-based workplace screening to identify patients at the earliest stages of
beryllium sensitization and disease. Environ Health Perspect 104(Suppl 5):937-943 (1996)
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Introduction
In the past decade we have witnessed a
resurgence of interest in beryllium's effects
on human health coincident with the real-
izations that disease due to beryllium con-
tinues to occur in industry and that we can
use our emerging understanding of the
immune system to better detect and diag-
nose beryllium-related disorders. Chronic
beryllium disease (CBD) is a systemic
granulomatous disorder that affects the
lungs predominantly. New cases continue
to be identified despite historical improve-
ments in workplace exposure conditions.
Following exposure to beryllium, between
1 and 16% of exposed workers become
sensitized to beryllium, as demonstrated
using an in vitro measure ofthe beryllium-
specific cell-mediated immune response
called the beryllium lymphocyte prolifera-
tion test (BeLPT), formerly the beryllium
lymphocyte transformation test (1-7). T
lymphocytes recognize beryllium as an
antigen triggering cell proliferation, release
ofinflammatory mediators, and accumula-
tion of inflammatory cells in the target
organ. This results in formation ofthe typ-
ical pathologic lesion, the noncaseating
granuloma, as well as the accumulation of
mononuclear cell infiltrates and fibrosis
(Figure 1). CBD can be thought of as a
beryllium-specific, cell-mediated immune
response gone awry.
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Although researchers first speculated
on the immune basis of this disorder
nearly 50 years ago (8), only in the last
decade have we been able to capitalize on
the immunopathogenesis of CBD in
detecting disease at its earliest stages and in
redescribing its natural history (6). Past
notions about the natural history of CBD
were constrained by the tools available to
clinicians of the 1940s and 1950s. With
the advent of immunologic testing for
beryllium sensitization (6,9), we may now
take a fresh look at this disorder starting
with some of its earliest biological effects.
What emerges is a portrait of CBD that
begins with exposure, leads to sensitization,
and culminates in the clinically apparent
granulomatous and fibrotic disease
described by Hardy and colleagues in the
1940s (10-12). It is now apparent that the
natural history of CBD does not begin
with an abnormal chest X-ray or pul-
monary function test (PFT), but starts
much earlier when the immune system first
recognizes beryllium particles as foreign
invaders and mounts its stereotypical
response to the antigen.
Having learned how to detect sensiti-
zation and disease early, new questions
arise, to which answers are emerging: a)
What is the natural history of beryllium
sensitization? b) Does sensitization lead to
clinical CBD? c) What is the natural his-
tory of subclinical CBD-does it neces-
sarily progress to a clinically apparent
illness? d) What host or exposure factors
influence the natural history ofsensitization
and ofCBD? e) Are there biological mark-
ers that can help predict the natural history
ofCBD? andf) Will early detection, using
the BeLPT as a screening tool, alter the nat-
ural history ofCBD? Armed with answers
to these questions, we will be better able to
chart a course toward both primary and sec-
ondary prevention ofCBD.
This article will review what was
known about the natural history ofclinical
CBD in the era that preceded the use of
immunologic markers, review data from
recent studies of patients with beryllium
sensitization and early disease, and summa-
rize the methodology being used in ongo-
ing longitudinal studies designed to address
some ofthe questions listed above.
Lessonsfrom Past Studies
of CBD Natural History
As mentioned, pioneers in the study of
CBD accurately described the clinical pic-
ture ofthis disorder in the 1940s and 1950s,
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Figure 1. Proposed sequence of pathologic events resulting in chronic beryllium disease. Photomicrograph (A), normal lung from a beryllium-sensitized individual (pen-
tachrome stain, 40x); (B), early pathologic changes in chronic beryllium disease in which there is a diffuse mononuclear cell interstitial infiltration of the lungs with formation
of some multinucleated giantcells, epithelioid cells and lymphocyte aggregates. Hematoxylin and eosin, 1Ox. (Continuedon nextpage)
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Figure 1 (continued). Proposed sequence of pathologic events resulting in chronic beryllium disease (C), Later disease showing more typical, well-formed noncaseating
granulomas with surrounding areas of mononuclear cell interstitial infiltration and varying degrees of fibrosis. Hematoxylin and eosin, lOx. (D), Pentachrome stain of non-
caseating granulomas demonstrates the dense circumferential accumulation ofcollagen (yellow) surrounding the granulomas. Pentachrome, 40x.
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using medical history, physical examination,
chest radiograph, and pulmonary function
testing. More sophisticated tests such as
computed tomography (CT) scanning,
immunologic tests like the beryllium lym-
phocyte proliferation test (BeLPT), and
measures of the pulmonary inflammatory
response such as bronchoalveolar lavage
(BAL) enhance our ability to identify and
study early disease. However, these earlier
works offer a valuable depiction of the
natural history beginning with the first
clinically obvious signs ofCBD (10-12).
At the Sixth Saranac Symposium, in
1947, Hardy reported her first observations
ofCBD natural history (11). Patients pre-
sented typically with a combination ofres-
piratory and systemic symptoms, most
commonly including weight loss, dyspnea,
anorexia, cough, chest pain, and fatigue.
Clinical signs frequently included cyanosis,
hypertrophic osteoarthropathy (digital
clubbing), and dry bilateral rales on auscul-
tation. Lymphadenopathy, hepatomegaly,
splenomegaly, skin lesions, and thy-
romegaly were found, but less frequently.
The cases characterized in the 1940s and
1950s were severe and detected at a late
stage, as reflected by the frequency with
which patients "presented" with evidence of
right-sided heart failure and cor pulmonale.
Typically, the clinical cases of CBD at
that time presented first with weight loss
and shortness ofbreath, later followed by
PFT changes and by abnormalities in the
chest radiograph (10,11). When pul-
monary physiologic alterations developed,
patients were found to have different pat-
terns. Some had normal lung volumes and
airflow but abnormal gas exchange as
reflected by the diffusing capacity for car-
bon monoxide (DLCo) (13) or by arterial
blood gas analysis at rest and with exercise
(14,15). Others developed air flow limita-
tion first, followed later by a restriction in
lung volumes. Others who presented with
more advanced disease showed a predomi-
nantly restrictive pattern. When chest
radiographs became abnormal, the paren-
chymal pattern ranged from diffuse fine
nodular opacities to larger nodules. These
nodules eventually consolidated into larger
masses associated with local pleural and sub-
pleural thickening. Hilar and mediastinal
adenopathy was common but not uniformly
present. Notably, patients presented often
with symptoms and PFT abnormalities in
advance ofany radiographically apparent
abnormalities, suggesting that the chest
radiograph was a relatively insensitive
marker of disease severity. Alternatively,
some patients had abnormal chest radi-
ographs but were asymptomatic, or symp-
tomatic without abnormalities on routine
spirometry. The conclusion drawn by
Hardy in 1955 was that the natural history
ofCBD varies among affected individuals
(12). Although data were not shown, that
article suggested that some patients with
abnormal chest radiographs could remain
free of "disability." Unfortunately, no
information exists concerning the degree to
which more sensitive tests ofpulmonary
physiologic derangement such as exercise
physiology with measurement of arterial
oxygenation were employed. Furthermore,
it was suggested that some individuals may
"recover" from CBD either "with residual
evidence ofirreversible pathology" or with
"no evidence ofdisease." Again, there is a
lack of primary data showing how these
conclusions were drawn.
Taken in composite, the medical litera-
ture suggests that once CBD is clinically
apparent, it will continue to progress ifleft
untreated. Does spontaneous remission
occur? In 1978, Sprince and colleagues
reported that the chest radiographic abnor-
malities disappeared in 9 of 18 untreated
patients within 3 years ofreduced exposure.
Gas exchange abnormalities improved in 13
of 20 who had arterial hypoxemia (16).
Unfortunately these cases had only limited
assessments. Only four had biopsy confir-
mation of disease and no cases received
immunologic assessment to lend greater
specificity to the diagnoses. In a briefreport
by Nishikawa in 1980, CBD was con-
firmed in eight cases by lung biopsy and
blood BeLPT. Two of the eight cases
showed radiographic clearing within one
year of removal from exposure (17). In
1969, Stoeckle described a case of com-
plete remission of CBD but only after
treatment with adrenocorticotrophic hor-
mone (ACTH) (18). Taken together, these
studies suggest that under some circum-
stances, patients with CBD may undergo
remission or at least clinically stabilize
upon removal from exposure, although
most studies indicate that disease progres-
sion is the general rule even after the
patient leaves theworkplace (19,20).
Published mortality rates for CBD
range from 5.8 to 38%. This wide varia-
tion is influenced in part by the duration of
clinical follow-up, but there is some evi-
dence that characteristics or type of expo-
sure may affect mortality as well. In 1958,
Peyton and colleagues reported on the
mortality in 561 occupational cases of
beryllium disease, including 240 acute
cases (forwhom the mortality rate was 7%)
and 348 CBD cases. In the CBD group as
a whole, 28% died. The mortality rate was
18% among beryllium extraction workers,
28% among fluorescent lamp workers, and
38% among those working with beryllium
alloys, beryllia ceramics, or in research and
development. Unfortunately, the authors
did not indicate the number ofyears that
elapsed between diagnosis and death (19).
The reason for the apparent differences in
the mortality rates by industry remains an
enigma. We do not yet know if the early
detection ofCBD will lead to earlier thera-
peutic intervention with corticosteroids
and a lower mortality rate (below).
Several important conclusions can be
drawn from the past studies of CBD nat-
ural history. First, the disease varies in its
clinical presentation. Second, the disease
varies in its rate of progression. Not all
patients progress, but if they do, some
deteriorate faster than others. While some
die within a few years ofdiagnosis in respi-
ratory failure and cor pulmonale, others
experience a more insidious downhill course
extending over decades. Third, while
removal from exposure may be medically
prudent, it is not known to what extent
such restrictions will change the natural his-
tory for more than a minority ofpatients.
Fourth, the earlier studies did not systemat-
ically examine the risk factors for disease
progression, such as smoking status; gender;
race; genetic makeup; duration, magnitude,
or type ofexposure; industry in which expo-
sure occurred; or mixed exposures to other
metals, solvents, cutting fluids, etc.
Based on past clinical studies and
anecdotes, it is reasonable to hypothesize
that a number offactors may affect the nat-
ural history ofCBD. These may include the
industry in which the exposure occurred,
the magnitude, frequency, and duration of
the exposure, principles ofparticle size and
solubility, as well as possible host factors
such as genetic makeup, smoking habits,
and, as suggested by Hardy, intercurrent
life stresses such as pregnancy/lactation,
combat, and surgery. More data are needed
to examine such questions. What is the
relevance ofthe past studies ofnatural his-
tory to our understanding of CBD today?
The industry has changed. Fluorescent
lamps no longer contain beryllium phos-
phors, although a large number ofthe cases
upon which the past studies ofnatural his-
tory are based were fluorescent lamp work-
ers (21). Today, cases originate increasily in
secondary use industries such as machining
of the metal and its alloys, dental alloy
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preparation, and ceramics. Although disease
still occurs, the mean level ofexposure has
been lower in the 1980s and 1990s than in
previous decades, at least for most beryl-
lium users. Some ofthe cases ofCBD ini-
tially presented with acute beryllium
pneumonitis (21) that progressed into the
chronic disease, whereas acute disease is
now distinctly rare. Earlier studies relied
upon a case definition that was prone to
potential misclassification, leading to the
possibility that some cases follow a different
course because they have a different etiol-
ogy. In addition, the natural history studies
were usually conducted as a series ofcross-
sectional analyses of the U.S. Beryllium
Disease Case Registry, not as a true longitu-
dinal study tracking natural history within
individuals. With the availability of
immunologic tests, in the 1980s it became
possible to define CBD with much greater
specificity. Furthermore, by using the blood
BeLPT, the disease that is studied today is
identified at a much earlier stage than has
been described prior to the late 1980s.
We conclude that ifwe are to under-
stand the natural history ofCBD as we will
know it in decades to come, it will be nec-
essary to take a fresh approach that a) relies
upon the best available case definition, one
that lends the greatest specificity without
unnecessarily excluding cases; b) focuses on
cases that are identified as only being sensi-
tized to beryllium without evidence ofdis-
ease; c) employs the most sensitive
physiologic, radiographic, and laboratory
tests available to track disease progression;
d) has a longitudinal, not cross-sectional,
design; and e) concomitantly tracks demo-
graphic variables and covariants such as
smoking and exposure that may influence
natural history.
Recent Studies Pertaining
to CBD Natural History
Several important clinical and epidemio-
logic investigations have helped set the stage
for the conduct of studies that meet the
needs described above. In the mid-1980s,
our group worked to improve the blood
BeLPT such that it could be used to screen
large numbers ofexposed workers for evi-
dence of beryllium sensitization (22).
Reasons for using the BeLPT and a discus-
sion of its merits and limits are presented
elsewhere in this supplement (23). We
have conducted studies of3 groups to date:
a pilot study ofnuclear weapons workers, a
subsequent study of 895 ofthese workers,
and population-based studies in two beryl-
lia ceramics plants. Through this series of
investigations, Kreiss, Newman, and co-
workers demonstrated that it was possible
to identify individuals who are sensitized
but who do not have disease, to identify
individuals with subclinical illness, and to
correct missed diagnoses in more advanced
cases ofdisease (2,3,6,22). In one of these
population-based studies, we examined the
positive and negative predictive value ofthe
various clinical tests that physicians use to
screen for beryllium disease in industry (3).
The only test with high positive and nega-
tive predictive value was the blood BeLPT.
As expected based on the earlier case series,
the chest radiograph was relatively insensi-
tive. Spirometry, symptom reporting, and
clinical examination had even lower posi-
tive predictive values. We concluded that to
identify and track the natural history of
beryllium sensitization and disease, it is
necessary to develop more sensitive clinical
and biological indicators ofdisease activity
and progression. This led to a series of
studies ofthe merits ofother clinical testing
modalities for detecting the clinical conse-
quences ofsensitization and early disease.
Toward the goal of developing more
sensitive markers of severity and progres-
sion, Pappas and Newman reexamined the
utility of pulmonary function testing,
DLCo, and exercise testing with indwelling
arterial line in both the early and the
advanced stages of CBD (24). They
observed that 57% ofCBD patients identi-
fied through workplace screening with the
BeLPT have measurable physiologic abnor-
malities at the time ofdiagnosis, support-
ing the value of early detection as a means
of finding clinically relevant disease. The
most common physiologic derangements
in early CBD were found in the measures
ofgas exchange: rising dead space to tidal
volume ratio during exercise and abnormal
fall of the PaO2 and rise in the alveolar-
arterial oxygen gradient (A-a) during exer-
cise. By comparison, spirometry, body
plethysmographic lung volumes, and
DLCo proved insensitive (24). These
observations were consistent with the phys-
iologic changes seen in CBD in the 1940s
by Wright and colleagues (14,15). While
exercise testing is relatively time consum-
ing, expensive, and invasive, the informa-
tion obtained is far superior to that
achieved using the conventional tools of
pulmonary medicine (24). Such testing is
needed to determine ifa patient with early
disease has physiologic impairment or if
the disease is progressing. Preliminary
results from our longitudinal study dis-
cussed below suggest that measures of gas
exchange and exercise limitation provide a
more sensitive means of tracking changes
in CBD over time.
Conventional chest radiography is
insensitive in detecting CBD. We recently
examined whether thin-section CT would
improve our ability to recognize CBD non-
invasively (25). Chest radiography was
compared with thin-section CT in a group
of 15 CBD patients who had abnormal
chest radiographs and a second group of 13
patients who had normal chest radiographs
as read by certified B-reader using the
International Labor Organization (ILO)
Classification. In the group with normal
chest X-rays, CT detected one or more of
the following abnormalities in three-quar-
ters of the patients: nodules, septal lines,
areas of ground-glass attenuation, and
bronchial wall thickening. The clinically
advanced cases showed more nodules and
septal lines (a result of fibrosis) than the
early, X-ray-normal cases. We conclude
that thin-section CT is relatively more sen-
sitive than plain radiography. CT may be
helpful in gauging the severity ofearly dis-
ease and warrants further study as a means
ofmonitoring disease progression. The CT
still misses up to one-quarter of biopsy-
proven cases of CBD identified through
workplace screening with the BeLPT.
Thus, a negative scan should not be used
to decide against biopsying patients with
abnormal BeLPTs.
In sarcoidosis, a granulomatous disease
of unknown etiology, serum angiotensin
converting enzyme (SACE) activity is fre-
quently elevated and has been associated
with the body burden of granulomas.
Similarly, SACE is elevated in patients
with CBD. But in one study that included
patients with early disease, only 22% had
abnormally elevated SACE levels (26).
The SACE activity, however, correlated
with the severity ofpulmonary physiologic
and radiographic abnormalities in CBD,
suggesting that it may prove useful as a bio-
logical marker of disease progression or of
response to therapy. This warrants further
study in the longitudinal examination of
natural history in CBD. Similarly, it may be
possible to use other blood indicators ofthe
magnitude ofthe inflammatory response or
the degree oflymphocyte activation as non-
specific biomarkers ofdisease severity and
disease progression. Promising candidates
include measures ofkey proinflammatory
cytokines known to be present in increased
amounts in the lungs ofpatients with CBD,
including tumor necrosis factor-a, and
interleukin-6 (27).
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CBD is characterized by the develop-
ment of large numbers of lymphocytes
within the lungs. This can be measured by
bronchoalveolar lavage (BAL), which is a
process ofinstilling fluid into a portion of
lung through a bronchoscope, withdrawing
the fluid, and counting the numbers and
types of cells recovered (6,28,29). The
BAL cellularity and lymphocytosis reflects
the degree of pulmonary inflammation.
Inflammation results in injury and in phys-
iologic impairment. It stands to reason that
ifwe measure directly the magnitude ofthe
inflammatory response in the lungs of
patients with sensitization or with CBD,
we might predict the effects of inflamma-
tion on lung physiology and physical
impairment. In a recent study of a large
number of patients with CBD, we began
to address this question by comparing the
BAL findings at the time ofdiagnosis with
other clinical parameters such as pul-
monary function testing, DLCo, chest radi-
ograph profusion of small opacities, and
measures of exercise tolerance and gas
exchange during exercise (28). The data
suggest that the higher the number of
white blood cells and lymphocytes in the
BAL, the more severe the exercise limita-
tion, A-a gradient, PaO2, and DLCo
abnormalities in CBD. Future studies will
examine whether these baseline BAL mea-
sures predict change in pulmonary physio-
logic impairment over time.
Longitudinal Study ofthe
Natural History of Beryllium
Sensitization and CBD
As a result ofthe population-based studies
by Kreiss and colleagues, we can now initi-
ate a longitudinal study ofberyllium sensi-
tization and early CBD. This study, being
conducted at National Jewish Center for
Immunology and Respiratory Medicine,
has three goals: to determine the natural
history of sensitization and disease, to
determine the best predictors of disease
progression, and to determine the host and
environmental factors that may modify the
risk ofdisease progression. We hypothesize
that sensitization leads to clinical CBD;
that CBD progression varies among indi-
viduals, i.e., that the natural history is
nonuniform; and that it is possible to iden-
tify individuals at greatest risk for disease
progression using biological markers ofthe
inflammatory and immune response.
Figure 2 outlines schematically the likely
sequence ofevents in CBD and the poten-
tial outcomes that we would expect to
observe longitudinally.
Since 1986, this longitudinal, observa-
tional study has enrolled all new cases of
beryllium sensitization or ofbiopsy-proven
CBD in a research protocol that measures
annually: (1) symptoms, occupational and
environmental exposures, and personal risk
factors, (2) physical findings, (3) spirometry
and body plethysmographic lung volumes,
(4) DLCo, (5) exercise capacity on a cycle
ergometer with indwelling arterial line for
blood gas analysis, (6) chest radiograph pro-
fusion of small opacities, (7) SACE, (8)
blood BeLPT, (9) BAL variables including
the cell count, differential, T cell subsets,
BeLPT, as well as analyses of other cell-
associated markers ofinflammation and cell
activation, and (10) transbronchial biopsy
in the sensitized group. Baseline evaluation
also includes thin-section CT scanning.
To date, this study has enrolled a total
of 99 patients, 72 ofwhom have clinical
CBD, 50 with disease detected through
workplace screening, and 22 with sensitiza-
tion alone. The mean age is 52 years (range
32-80 years). Reflecting the general work-
force at the industrial plants screened, the
demographic distribution is predominantly
Caucasian and male. The groups are equally
divided among ever- and never-smokers
with the exception that there are more ever-
and current-smokers in the sensitized,
nondisease group. Subjects are divided
equally between those exposed in the
ceramics industry and those exposed in the
manufacture ofnuclear weapons or through
other metal machining-related operations.
Figure 2. Proposed schema of the events and out-
comes for individuals exposed to beryllium. Solid lines
indicate known outcomes. Broken lines indicate hypo-
thetical outcomes. Note that some individuals with
early disease may stabilize but be left with some
degree of impairment and disability. Corticosteroids
may have an effect on progressive disease, but their
role in early disease management is not known.
While half the clinical CBD cases are on
corticosteroids at the time of enrollment,
fewer than 10% ofthe CBD subjects who
enter through workplace screening pro-
grams are on treatment with either oral or
inhaled forms when they enroll.
Preliminary Conclusions
The mean duration of follow-up of these
cohorts as of October 1994 has been 2.8
years for the clinical CBD group, 2.8 years
for the screening-identified CBD group,
and 2.3 years for the sensitized only group.
Thus, it is too early to draw many conclu-
sions from this study of a slowly progres-
sive, chronic disorder. Nonetheless, several
preliminary, qualitative conclusions can be
made at this time based on the longitudinal
data and based on the population-based
studies discussed above.
First, sensitization can occur in the
absence ofCBD (2). We follow 22 patients
who clearly had repeatedly abnormal blood
BeLPTs but who had no symptoms, no
physical abnormalities, and normal spirom-
etry, PFTs, DLCo, exercise capacity, gas
exchange, chest radiographs, bronchoalveo-
lar lavage, and even normal lung biopsies at
the time ofentry in the study.
Second, sensitization can progress into
clinical CBD (9). Although the duration of
follow-up has been relatively short to deter-
mine the rate at which this occurs, of the
six individuals sensitized who have been
followed for more than 5 years, three have
developed CBD based on the emergence of
abnormal clinical findings, symptoms,
physiology, and increasingly lymphocytic
lavage and noncaseating granulomas on
lung biopsy. Not all patients with sensitiza-
tion have developed CBD, but a longer
period of follow-up will be needed to
determine the frequency with which pro-
gression to CBD occurs.
Third, after exposure to beryllium, for
those patients who develop CBD, the bio-
logical alterations occur in the following
sequence: development of beryllium-spe-
cific immunity; gradual emergence of a
chronic inflammatory response within the
target organ, e.g., lung; pathological alter-
ations in the target organ; measurable
physiologic derangement; disability; and in
some cases, death.
Fourth, we conclude that it is feasible
to conduct a longitudinal study of the
natural history of sensitization and CBD,
but that due to the rate ofdisease progres-
sion and the variability between individu-
als, a long period of study and a large
number ofstudy subjects will be required.
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Given the absence ofgood data concerning
the natural history and the variables that
may affect outcome, such studies are
needed. We hope that early intervention
will prevent long-term disability and death
for the many sensitized and diseased
patients identified through workplace
screening and surveillance efforts.
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